New progress in the treatment of hypertrophic obstructive cardiomyopathy#br#
CHEN Meng1 LIU Huihui2 JIANG Zhixin1 SHAN Qijun1
1.Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province, Nanjing 210029, China;
2.Department of Cardiology, Rugao People’s Hospital, Jiangsu Province, Rugao 226500, China
Abstract：Hypertrophic cardiomyopathy is a genetic disease, high incidence in the population. Among them, hypertrophic obstructive cardiomyopathy is harmful, in addition to causing chest pain, syncope, and other clinical symptoms, severe cases can cause sudden death. With the further study of the pathogenesis, much progress has been made in the treatment of outflow tract obstruction, both pharmacological and non-pharmacological, such as Mavecamten precision biology drug therapy and apical percutaneous cardiac interventricular radiofrequency ablation. Combined with the latest relevant research, in this paper, drug therapy, interventional therapy, radiofrequency ablation, and gene therapy of hypertrophic obstructive cardiomyopathy were systematically described, in order to improve the understanding of the treatment and research of the disease.
[1] Chung H，Kim Y，Cho SM，et al. Differential Contributions of Sarcomere and Mitochondria-Related Multigene Variants to the Endophenotype of Hypertrophic Cardiomyopathy [J]. Mitochondrion，2020，53：48-56.
[2] Moon I，Lee SY，Kim HK，et al. Trends of The Prevalence and Incidence of Hypertrophic Cardiomyopathy in Korea：A Nationwide Population-based Cohort Study [J]. PLoS One，2020，15（1）：e0227012.
[3] Morentin B，Suarez-Mier MP，Monzo A，et al. Sports-related Sudden Cardiac Death due to Myocardial Diseases on a Population from 1-35 years：a Multicentre Forensic Study in Spain [J]. Forensic Sci Res，2019，4（3）：257-266.
[4] Khachfe HH，Salhab HA，Fares MY，et al. Current State of Hypertrophic Cardiomyopathy Clinical Trials [J]. Glob Heart，2019，14（3）：317-325.
[5] Elliott PM，Anastasakis A，Borger MA，et al. 2014 ESC Guidelines on Diagnosis and Management of Hypertrophic Cardiomyopathy The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology （ESC）[J]. Eur Heart J，2014， 35（39）：2733-2779.
[6] Rodriguez-Gonzalez M，Antonio Perez-Reviriego A，Castellano-Martinez A，et al. Disopyramide as Coadjuvant Treatment in Obstructive Hypertrophic Cardiomyopathy [J]. An Pediatr （Engl Ed），2021，94（4）：253-256.
[7] Green EM，Wakimoto H，Anderson RL，et al. A Small-Molecule Inhibitor of Sarcomere Contractility Suppresses Hypertrophic Cardiomyopathy in Mice [J]. Science，2016， 351（6273）：617-621.
[8] Heitner SB，Jacoby D，Lester SJ，et al. Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy A Clinical Trial [J]. Ann Intern Med，2019，170（11）：741-748.
[9] Sparrow AJ，Watkins H，Daniels MJ，et al. Mavacamten Rescues Increased Myofilament Calcium Sensitivity and Dysregulation of Ca2+ flux Caused by Thin Filament Hypertrophic Cardiomyopathy Mutations [J]. Am J Physiol Heart Circ Physiol，2020，318（3）：H715-H722.
[10] Ho CY，Olivotto I，Jacoby D，et al. Study Design and Rationale of EXPLORER-HCM Evaluation of Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy [J]. Circ Heart Fail，2020，13（6）：e006853.
[11] De Diego C，González-Torres L，Nú?觡ez JM，et al. Effects of Angiotensin-Neprilysin Inhibition Compared to Angiotensin Inhibition on Ventricular Arrhythmias in Reduced Ejection Fraction Patients under Continuous Remote Monitoring of Implantable Defibrillator Devices [J]. Heart Rhythm，2018，15（3）：395-402.
[12] Mcmurray JJV，Solomon SD，Inzucchi SE，et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction [J]. N Engl J Med，2019，381（21）：1995-2008.
[13] Ommen SR，Mital S，Burke MA，et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy：Executive Summary：A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [J]. Circulation，2020，142（25）：e533-e557.
[14] Antal A，Boyacioglu K，Akbulut M，et al. Surgical Management of Hypertrophic Obstructive Cardiomyopathy [J]. Gen Thorac Cardiovasc Surg，2020，68（9）：962-968.
[15] Song HK，Turner J，Macfie R，et al. Routine Papillary Muscle Realignment and Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy [J]. Ann Thorac Surg，2018，106（3）：670-675.
[16] Nishimura RA，Seggewiss H，Schaff HV. Hypertrophic Obstructive Cardiomyopathy Surgical Myectomy and Septal Ablation [J]. Circ Res，2017，121（7）：771-783.
[17] El-Sabawi B，Nishimura RA，Barsness GW，et al. Temporal Occurrence of Arrhythmic Complications After Alcohol Septal Ablation [J]. Circ Cardiovasc Interv，2020， 13（2）：e008540.
[18] D?諭browski M，Kuku?覥a K，K?覥opotowski M，et al. Reduction of Left Ventricular Mass，Left Atrial Size，and N-terminal pro-B-type Natriuretic Peptide Level Following Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy [J]. Kardiol Pol，2019，77（2）：181-189.
[19] Afanasyev AV，Bogachev-Prokophiev AV，Kashtanov MG，et al. Myectomy versus Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy [J]. Interact Cardiovasc Thorac Surg，2020，31（2）：158-165.
[20] Bytyci I，Nistri S，Morner S，et al. Alcohol Septal Ablation versus Septal Myectomy Treatment of Obstructive Hypertrophic Cardiomyopathy：A Systematic Review and Meta-Analysis [J]. J Clin Med，2020，9（10）：3062.
[21] 陈冉，蒋志新，单其俊.室间隔射频消融术：治疗梗阻性肥厚型心肌病的新选择[J].中华心血管病杂志，2017， 45（3）：186-189.
[22] Javidgonbadi D，Andersson B，Abdon NJ，et al. Morbidity and Resource Usage after Myectomy-or Pacing-Treatment in Hypertrophic Obstructive Cardiomyopathy：A Case-Control Study [J]. Int J Cardiol，2021，322：197-203.
[23] 刘丽文，左蕾，周梦垚，等.经胸超声心动图引导下经皮心肌内室间隔射频消融术治疗梗阻性肥厚型心肌病的安全性和有效性[J].中华心血管病杂志，2019，47（4）：284-290.
[24] Liu L，Zhou M，Zuo L，et al. Echocardiography Guided Liwen Procedure for the Treatment of Obstructive Hypertrophic Cardiomyopathy in a Patient with Prior Aortic Valve Replacement Surgery：Liwen Procedure for Intra-Myocardial Radiofrequency Ablation [J]. Echocardiography，2018，35（8）：1230-1232.
[25] Liu L，Liu B，Li J，et al. Percutaneous Intramyocardial Septal Radiofrequency Ablation of Hypertrophic Obstructive Cardiomyopathy：a Novel Minimally Invasive Treatment for Reduction of Outflow Tract Obstruction [J]. Eurointervention，2018，13（18）：E2112-E2113.
[26] Cooper RM，Shahzad A，Hasleton J，et al. Radiofrequency Ablation of the Interventricular Septum to Treat Outflow Tract Gradients in Hypertrophic Obstructive Cardiomyopathy：a Novel Use of CARTOSound?誖 Technology to Guide Ablation [J]. Europace，2016，18（1）：113-120.
[27] Lawrenz T，Borchert B，Leuner C，et al. Endocardial Radiofrequency Ablation for Hypertrophic Obstructive Cardiomyopathy Acute Results and 6 Months’ Follow-Up in 19 Patients [J]. J Am Coll Cardiol，2011，57（5）：572-576.
[28] 贾玉和，林瑶，刘俊，等.在心内三维超声指导下经皮心内膜室间隔射频消融术治疗肥厚型梗阻性心肌病合并晕厥的临床应用研究[J].中国循环杂志，2020，35（7）：638-644.
[29] Szumowski L，Dabrowski M，Tyczynski P，et al. Endocardial Radiofrequency Ablation for Septal Hypertrophy [J]. Kardiol Pol，2016，74（7）：700.
[30] Durand E，Mousseaux E，Coste P，et al. Non-Surgical Septal Myocardial Reduction by Coil Embolization for Hypertrophic Obstructive Cardiomyopathy：Early and 6 Months Follow-up [J]. Eur Heart J，2008，29（3）：348-355.
[31] Latsios G，Gerckens U，Mueller R，et al. Substitution of ethanol with specially designed microspheres in a TASH procedure [J]. Eurointervention，2011，6（7）：889-892.
[32] Vriesendorp PA，Van Mieghem NM，Vletter WB，et al. Microsphere Embolisation as An Alternative for Alcohol in Percutaneous Transluminal Septal Myocardial Ablation [J]. Neth Heart J，2013，21（5）：245-248.
[33] Maron BJ，Maron MS，Semsarian C. Genetics of Hypertrophic Cardiomyopathy After 20 Years Clinical Perspectives [J]. J Am Coll Cardiol，2012，60（8）：705-715.
京公网安备 11010502046598号